Chronic respiratory diseases in developing countries: the burden and strategies for prevention and management, Bull World Health Organ, vol.79, issue.10, pp.971-980, 2001. ,
International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma, Eur Respir J. févr, vol.43, issue.2, pp.343-73, 2014. ,
Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation, J Allergy Clin Immunol. 1 janv, vol.127, issue.1, pp.167-72, 2011. ,
Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire, Respir Med. 1 avr, vol.100, issue.4, pp.616-637, 2006. ,
Updated guidelines (2015) for management and monitoring of adult and adolescent asthmatic patients (from 12 years and older) of the Société de Pneumologie de Langue Française (SPLF) (Full length text), Rev Mal Respir. avr, vol.33, issue.4, pp.279-325, 2016. ,
Severe asthma in adults: what are the important questions?, J Allergy Clin Immunol. juin, vol.119, issue.6, pp.1337-1385, 2007. ,
Difficult asthma, Eur Respir J. nov, vol.12, issue.5, pp.1209-1227, 1998. ,
Severe asthma: epidemiology, burden of illness, and heterogeneity, Allergy Asthma Proc. déc, vol.36, issue.6, pp.418-442, 2015. ,
The prevalence of severe refractory asthma, J Allergy Clin Immunol. 1 avr, vol.135, issue.4, pp.896-902, 2015. ,
Effect of asthma on quality of life, Can Respir J. août, vol.5, 1998. ,
Clinical and economic burden of severe asthma: A French cohort study, Respir Med. nov, vol.144, pp.42-51, 2018. ,
URL : https://hal.archives-ouvertes.fr/hal-02061550
Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma, J Allergy Clin Immunol. janv, vol.111, issue.1, pp.87-90, 2003. ,
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE, Allergy. mars, vol.60, issue.3, pp.309-325, 2005. ,
Does omalizumab make a difference to the real-life treatment of asthma exacerbations?: Results from a large cohort of patients with severe uncontrolled asthma, Chest. 1 févr, vol.143, issue.2, pp.398-405, 2013. ,
Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, doubleblind, placebo-controlled trial, Lancet Lond Engl. 18 août, vol.380, issue.9842, pp.651-660, 2012. ,
Mepolizumab treatment in patients with severe eosinophilic asthma, N Engl J Med. 25 sept, vol.371, issue.13, pp.1198-207, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01785638
Benralizumab, an anti-interleukin-5 receptor ? monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, Lancet Lond Engl, vol.29, pp.2128-2169, 2016. ,
Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study. Chest, vol.150, pp.789-98, 2016. ,
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting ?2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial, Lancet Lond Engl. 2 juill, vol.388, pp.31-44, 2016. ,
Dupilumab in persistent asthma with elevated eosinophil levels, N Engl J Med. 27 juin, vol.368, issue.26, pp.2455-66, 2013. ,
European Position Paper on Rhinosinusitis and Nasal Polyps, Rhinol Suppl, vol.23, pp.1-298, 2012. ,
Rhinosinusitis: developing guidance for clinical trials, J Allergy Clin Immunol, vol.118, issue.5, pp.17-61, 2006. ,
The health and resource utilization of Canadians with chronic rhinosinusitis. The Laryngoscope, janv, vol.119, issue.1, pp.184-193, 2009. ,
French adaptation and validation of the sino-nasal outcome test-22: a prospective cohort study on quality of life among 422 subjects, Clin Otolaryngol Off J ENT-UK Off J Neth Soc Oto-Rhino-Laryngol Cervico-Facial Surg. févr, vol.40, issue.1, pp.29-35, 2015. ,
Chronic rhinosinusitis control from the patient and physician perspectives, Laryngoscope Investig Otolaryngol. déc, vol.3, issue.6, pp.419-452, 2018. ,
A cross-sectional, population-based survey of U.S. adults with symptoms of chronic rhinosinusitis, Allergy Asthma Proc. 14 janv, vol.40, issue.1, pp.48-56, 2019. ,
Factors of success of low-dose macrolides in chronic sinusitis: Systematic review and meta-analysis. The Laryngoscope, vol.11, 2019. ,
A double-blind, randomized, placebo-controlled trial of macrolide in the treatment of chronic rhinosinusitis. The Laryngoscope, févr, vol.116, issue.2, pp.189-93, 2006. ,
Real-life study showing uncontrolled rhinosinusitis after sinus surgery in a tertiary referral centre, Allergy. févr, vol.72, issue.2, pp.282-90, 2017. ,
Treating allergic rhinitis with depot-steroid injections increase risk of osteoporosis and diabetes, Respir Med. déc, vol.107, issue.12, pp.1852-1860, 2013. ,
Monoclonal antibodies for the treatment of chronic rhinosinusitis with nasal polyposis: a systematic review, Rhinology. 1 mars, vol.56, issue.1, pp.11-21, 2018. ,
Long-term risk factors for developing asthma and allergic rhinitis: a 23-year follow-up study of college students, Allergy Proc Off J Reg State Allergy Soc. févr, vol.15, issue.1, pp.21-26, 1994. ,
, European Community Respiratory Health Survey II Steering Committee. The European Community Respiratory Health Survey II, Eur Respir J. nov, vol.20, issue.5, pp.1071-1080, 2002.
Allergic rhinitis and asthma: how important is the link?, J Allergy Clin Immunol. févr, vol.99, issue.2, pp.781-786, 1997. ,
Treatment of chronic rhinosinusitis and its effects on asthma, Eur Respir J. juill, vol.28, issue.1, pp.68-74, 2006. ,
Asthma and the unified airway. Otolaryngol--Head Neck Surg Off J Am Acad Otolaryngol-Head Neck Surg, vol.136, pp.75-106, 2007. ,
Eosinophilic inflammation in asthma, N Engl J Med, vol.323, issue.15, pp.1033-1042, 1990. ,
Nasal biomarker profiles in acute and chronic rhinosinusitis, Clin Exp Allergy J Br Soc Allergy Clin Immunol. sept, vol.35, issue.9, pp.1186-91, 2005. ,
IL-5 synthesis is upregulated in human nasal polyp tissue, J Allergy Clin Immunol. juin, vol.99, issue.6, pp.837-879, 1997. ,
Presence of IL-5 protein and IgE antibodies to staphylococcal enterotoxins in nasal polyps is associated with comorbid asthma, J Allergy Clin Immunol, vol.126, issue.5, pp.1-6, 2010. ,
ECDEU assessment manual for psychopharmacology, Public Health Service, 1976. ,
A randomized, double-blind, placebo-controlled trial of anti-IgE for chronic rhinosinusitis, Rhinology. sept, vol.48, issue.3, pp.318-342, 2010. ,
Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma, J Allergy Clin Immunol. janv, vol.131, issue.1, pp.110-116, 2013. ,
Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis, J Allergy Clin Immunol, vol.128, issue.5, pp.989-995, 2011. ,
Reduced need for surgery in severe nasal polyposis with mepolizumab: Randomized trial, J Allergy Clin Immunol, vol.140, issue.4, pp.1024-1031, 2017. ,
Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps, J Allergy Clin Immunol, vol.118, issue.5, pp.1133-1174, 2006. ,
MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function, J Allergy Clin Immunol. juin, vol.125, issue.6, pp.1344-1353, 2010. ,